Browse the evidence

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GLP-1 receptor agonists exhibit neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, potentially by crossing the blood-brain barrier and reducing amyloid-beta accumulation.

Current evidence for neuroprotection from GLP-1 agonists comes primarily from animal studies, showing potential to protect against Alzheimer's and Parkinson's disease mechanisms. While promising, clinical data in humans is still limited, and these drugs are not yet approved for cognitive disorders.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.

Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.

Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

Synthetic agonists of the NR4A subgroup (e.g., 6-mercaptopurine, cytosporone B) can modulate receptor activity to potentially treat metabolic and cardiovascular diseases, although their clinical utility is currently limited by poor potency and lack of endogenous ligand specificity.

Researchers have identified synthetic drugs that can activate NR4A receptors, which might help treat obesity and diabetes in the future. However, these drugs are currently just research tools with weak effects and unknown long-term safety. For now, the best way to activate these beneficial receptors is through natural stimuli like exercise and healthy eating, which the body is evolved to handle.

Current assays for measuring testosterone and free testosterone in women are inadequate due to lack of sensitivity and specificity, necessitating the development of more accurate methods.

Be aware that standard testosterone tests may not be accurate for women because they are designed for higher male levels. If you are concerned about hormone levels, ask your doctor about the limitations of the test used and whether more sensitive methods (like mass spectrometry) are available.

Inhibitors of histone deacetylases (HDACs) can restore lost memories and reverse cognitive phenotypes in mouse models of Alzheimer's disease by targeting locus-specific chromatin alterations.

Current research indicates that HDAC inhibitors show promise in restoring memory in animal models of Alzheimer's. However, these are experimental therapies not yet available for human use. Focus on proven lifestyle interventions like exercise and cognitive engagement to support brain health.

Better neighborhood social environments (safety, social cohesion, aesthetic quality) are not consistently associated with lower BMI, and in men, are associated with higher BMI.

Don't assume that moving to a 'safer' or 'nicer' neighborhood will automatically help you lose weight. For men, this study even found a link to higher BMI. Focus on controllable factors like diet and exercise rather than relying on social environment metrics for weight management.

Obesity-associated DNA damage in germ cells (sperm and oocytes) can be transmitted to offspring, potentially causing de novo mutations and affecting the health of future generations.

If you are obese and planning to have children, your current health status can impact your child's genetic health. Obesity can cause DNA damage in sperm and eggs, which may lead to mutations or metabolic issues in the child. Preconception weight management and healthy lifestyle choices can help reduce these risks for your future offspring.

Elevated skeletal muscle expression of myostatin, but not ubiquitin proteasome components, is a key molecular mechanism driving post-liver transplantation sarcopenia.

This finding suggests that post-transplant muscle loss might be driven by hormonal signals (myostatin) rather than just protein breakdown. While this is based on a very small group, it hints that future treatments might need to target these specific hormones to help patients regain muscle mass after surgery.

Antibiotic treatment (specifically norfloxacin and ampicillin) improves fasting blood glucose and oral glucose tolerance in obese, insulin-resistant mice by reducing plasma LPS levels and intestinal inflammation.

While antibiotics can improve glucose metrics in animal models by reducing gut inflammation, they are not a recommended treatment for humans due to side effects like weight gain. Focus on safer microbiota modulation through diet and probiotics instead.

Exercise-induced browning of subcutaneous white adipose tissue (ScAT) in rodents may serve as an adaptive mechanism to compensate for reduced insulation due to fat loss or to manage oxidative stress/redox state, rather than primarily for thermogenesis.

In animals, fat tissue changes during exercise might be a response to stress or inflammation rather than just burning calories. This doesn't change the advice: keep exercising for overall health, as the specific 'browning' mechanism is not proven to help humans lose weight.

Once-weekly subcutaneous semaglutide 2.4 mg produces clinically significant, sustained weight loss (mean -10.2% at 208 weeks) in adults with preexisting cardiovascular disease and obesity/overweight without diabetes, compared to placebo.

If you have heart disease and are overweight or obese (even without diabetes), once-weekly semaglutide 2.4 mg can help you lose about 10% of your body weight over 4 years, which is significantly more than placebo. This benefit is seen across different sexes, races, and BMI categories, though those with lower starting BMI might stop the medication more often due to side effects or lack of motivation. The key is that it works sustainably for cardiovascular health.

Semaglutide (2.4 mg/week) induces significant weight loss (mean -10.09% body weight) and improves cardiometabolic markers (BMI, waist circumference, blood pressure, CRP, lipids) in obese or overweight non-diabetic adults, with efficacy increasing with dose.

For non-diabetic adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, averaging a 10% reduction in body weight. It also improves blood pressure, inflammation (CRP), and lipid profiles. While gastrointestinal side effects like nausea are common, they are typically transient. The treatment is dose-dependent, with higher doses yielding greater weight loss.

Long-term use of FDA/Health Canada-approved obesity pharmacotherapies (semaglutide, tirzepatide, liraglutide, naltrexone-bupropion, orlistat) combined with health behavior changes produces clinically meaningful weight loss and prevents weight regain upon discontinuation.

If you have obesity (BMI ≥ 30, or ≥ 27 with health issues), talk to your doctor about FDA/Health Canada-approved weight loss medications like semaglutide or tirzepatide. These work best when combined with diet and exercise changes. Crucially, these are long-term treatments; stopping them usually leads to regaining the weight, so view them as a permanent tool for managing your health, not a quick fix.

Tirzepatide (5-15 mg weekly) produces superior weight loss compared to semaglutide and placebo in adults with obesity, with dose-dependent efficacy.

Tirzepatide is a weekly injection that can lead to significant weight loss (up to ~21% in trials). It works by targeting two hormones (GIP and GLP-1). Side effects like nausea are common but often temporary. It is approved for adults with obesity or overweight with health issues.